BCL2 and urinary bladder cancer: To analyze samples negative for BCL2 methylation, we expanded the MethyLight-based analysis by six additional promoter CpG islands previously reported to be frequently hypermethylated in bladder cancer, including CCNA1, EOMES, HOXA9, POU4F2, SALL3 and VIM2[16], [18], [23].